TITLE:
A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)

CONDITION:
Sepsis

INTERVENTION:
Drotrecogin Alfa (Activated)

SUMMARY:

      The purpose of this study is to evaluate the relative efficacy and safety of prophylactic
      heparin co-administration during drotrecogin alfa (activated) infusion in the treatment of
      severe sepsis in the adult.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

          -  Adults greater than or equal to 18 years of age

          -  Receiving inpatient treatment for severe sepsis

          -  Indicated for treatment with Drotrecogin Alfa (Activated) under approved label in the
             country where the patient is enrolled

        Exclusion Criteria

          -  Contraindicated for heparin treatment

          -  Require a higher dose of heparin than defined in the trial

          -  Have acute or chronic renal failure with an estimated creatinine clearance less than
             30mL/min

          -  Weigh more than 135 kg (297 pounds)

          -  Are not expected to survive 28 days given their medical condition.
      
